Akademik Veri Yönetim Sistemi
7th Eurasia Biochemical Approaches & Technologies (EBAT), Antalya, Türkiye, 6 - 09 Kasım 2025, ss.104, (Özet Bildiri)
Cancer remains one of the leading health problems worldwide, and despite advances in treatment, limitations and side effects of current therapies continue to pose challenges.1 Natural compounds have attracted considerable attention as alternative therapeutic agents due to their accessibility, low toxicity, and diverse biological activities.2 Lichens, traditionally used in medicine, produce secondary metabolites with well-documented anti-proliferative, pro-apoptotic, anti-metastatic, and anti angiogenic properties.3,4 The anticancer effect of lobaric acid (LA), one of the lichen acids, on human breast cancer has not yet been fully investigated. In this study, the anti-proliferative, pro-apoptotic, anti-migratory effects of LA and its effects on oxidative stress parameters (ROS, GSH, and MDA levels) were comprehensively investigated in MCF-7 breast cancer cells. XTT assay revealed a dose (0-100 μg/mL) and time (24 and 48 h) dependent decrease in cell viability, and the IC₅₀ value was calculated as 44.21 μg/mL at 48 h on MCF-7 cells. Flow cytometry analysis showed that LA induced apoptosis (p<0.001) and increased ROS levels (P<0.001). Wound healing assay showed that LA markedly suppressed migration of MCF-7 cells, with wound closure reduced to ~11%, ~5%, and ~2% at 6, 12, and 24 h, compared to ~26%, ~30%, and ~39% in the control group. Glutathione (GSH) levels (p<0.05) were found to be reduced in LA-treated cells compared to the control group, while malondialdehyde (MDA) levels (p<0.001) were significantly increased In conclusion, LA exhibits potent anticancer effects on MCF-7 cells by reducing cell viability, inducing apoptosis, increasing oxidative stress, and suppressing cell migration. These findings suggest that LA may serve as a promising natural compound for breast cancer therapy, potentially through modulation of apoptosis and oxidative stress pathways.